Hospitalizations

• The SPIRIT-HF study, presented at ACC.26 in New Orleans (March 28-30, 2026), found that spironolactone increased hospitalizations and serious adverse events in patients with HFpEF (heart failure with preserved ejection fraction) or HFmrEF (mildly reduced ejection fraction). • Results raise significant safety questions about the drug's efficacy in these patient populations, potentially challenging current treatment protocols. • The findings were presented to cardiologists and cardiovascular specialists at the American College of Cardiology's annual conference, the largest gathering of heart disease specialists.

• Respiratory syncytial virus (RSV) hospitalizations declined 42% in the week ending March 20, 2026, compared to the peak surge in February, according to CDC surveillance data. • The decline follows the introduction of the first RSV vaccines approved for adults over 60 and high-risk populations, with over 8 million doses administered since January. • RSV typically causes severe disease in infants and older adults; the new vaccines represent a major breakthrough after decades of failed vaccine development efforts.